Home » BIOGEN IDEC AND MONDOBIOTECH SIGN COLLABORATION AND LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE AVIPTADIL FOR PULMONARY ARTERIAL HYPERTENSION
BIOGEN IDEC AND MONDOBIOTECH SIGN COLLABORATION AND LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE AVIPTADIL FOR PULMONARY ARTERIAL HYPERTENSION
Biogen Idec and mondoBIOTECH AG, a private Swiss biotechnology company, announced the signing of an exclusive collaboration and license agreement for Biogen Idec to develop, manufacture and commercialize Aviptadil, a clinical compound for the treatment of Pulmonary Arterial Hypertension (PAH). BioWire (http://home.businesswire.com/portal/site/biowire2k/index.jsp?epi-content=GENERIC&newsId=20060914005288&ndmHsc=v2*A1157626800000*B1158286522000*DgroupByDate*J2*N1000155&newsLang=en&beanID=760679408&viewID=news_view)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct